Search Results
Your search for ,FeW matches 3159 pages
Showing 1 - 50Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer
Five-treatment stereotactic body radiation therapy (SBRT) may offer an effective alternative to surgery for patients with localized prostate cancer. In long-term follow-up findings from the phase III PACE-A trial presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting...
Ultra–Low-Dose Radiation Therapy May Relieve Bone Pain From Multiple Myeloma
A short course of ultra–low-dose radiation therapy relieved painful bone lesions from multiple myeloma for patients in a multi-institutional phase II clinical trial. The findings suggest that a lower-intensity approach could help ease patients’ pain without interrupting other treatment and with few ...
I Wasn’t Expecting Cancer at 22
Before I was diagnosed with advanced stage ovarian ependymoma, in 2025, when I was just 22, I didn’t know anything about cancer. I knew a few older adults who had had cancer, but that was the extent of my knowledge about the disease. Even to this day, I’m not sure I’ve completely wrapped my head...
How One Nonprofit Is Providing Access to a Discontinued Investigational Drug for Children With a Rare Form of AML
Blood Cancer United (formerly the Leukemia & Lymphoma Society) recently announced it had acquired the remaining supply and rights to the investigational agent luveltamab tazevibulin, an antibody drug conjugate targeting the folate receptor-1 alpha (FOLR1) molecule, from the drug’s manufacturer, ...
Germline EGFR T790M Associated With Significant Lung Cancer Risk
Researchers have found a significantly increased risk of lung cancer in individuals with an EGFR T790M germline variant, about 25 times higher than in noncarriers, according to study findings published in Science. “Today, lung cancer screening is driven almost entirely by smoking history,” said...
Robert A. Kyle, MD, Myeloma Expert, Dies at 98
The International Myeloma Foundation (IMF) shared news of the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
Biomarker Guides Treatment Sequencing, Predicts Outcomes in BRAF-Mutated Metastatic Melanoma
Using a blood test to track thymidine kinase activity may help determine optimal first-line treatment for patients with BRAF V600–mutated metastatic melanoma, according to findings published in Clinical Cancer Research. "The results suggest that thymidine kinase activity may help identify which...
Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy
New results from the international, randomized, phase III OPTIMA trial indicate that select patients with clinically high-risk, estrogen receptor–positive, HER2-negative early breast cancer who have a low risk of recurrence based on tumor gene expression testing may be able to safely avoid...
Charles W.M. Roberts, MD, PhD, Named President and Chief Executive Officer of St. Jude Children’s Research Hospital
The Board of Governors of St. Jude Children’s Research Hospital have announced Charles W.M. Roberts, MD, PhD, Executive Vice President and current Director of the St. Jude Comprehensive Cancer Center, as its next President and Chief Executive Officer. The announcement follows an extensive...
Can Newborn Genetic Testing Identify Cancer Predisposition Genes?
Expanding routine newborn screening to include genetic testing could identify genes associated with cancer risk and flag babies who may be at risk of later developing pediatric cancers, according to findings published in Nature Communications. Newborns in the United States routinely undergo...
Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
In the phase III BOND-003 Cohort C trial, intravesical cretostimogene grenadenorepvec, an oncolytic immunotherapy, produced complete responses in three-quarters of patients with high-risk, bacillus Calmette-Guérin (BCG)-unresponsive, non–muscle-invasive bladder cancer (NMIBC) with carcinoma in...
When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
A few weeks ago, a friend in the United States reached out to me about her sister in Rwanda, a woman in her 40s with no history of smoking. Her chest pain had progressively worsened to the point of becoming unbearable. CT imaging revealed a concerning lung mass highly suggestive of malignancy. One...
Next-Generation Sequencing Uptake Remains Low Among Medicare Beneficiaries, Study Finds
While there has been a recent increase among Medicare recipients in uptake of genomic testing that helps match patients with cancer to the most effective treatment for their tumor, many Medicare beneficiaries with cancer are still not receiving next-generation sequencing (NGS), according to a new...
The Fear of Having Cancer Never Goes Away
There is a strong history of breast cancer in my family, and the fact that I have dense breasts adding to my risk of developing the disease, kept me vigilant about getting a yearly mammogram screening since I turned 32. The test never showed any suspicious lesions over the last nearly 2 decades,...
Access Denied: Insurance Barriers to Biomarker Testing in Lung Cancer
In the past few decades, the rapidly growing field of precision medicine has improved the survival of patients with lung cancer. Yet the benefits of these therapies do not reach all patients. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, yet most patients are diagnosed ...
ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field
The plasma cell dyscrasia oral abstract session at the 2026 ASCO Annual Meeting featured several pivotal trials that advanced the field, including those highlighted here. Coverage of new treatments for amyloidosis will appear in a separate article. Mezigdomide-Based Regimen Improves...
Over 50 Million Americans Live in Counties Without a Radiation Oncology Clinic
More than 50 million Americans live in counties without a radiation oncology practice site and millions more are at risk, according to a new study published by Yu et al in the International Journal of Radiation Oncology • Biology • Physics (Red Journal). The national analysis found that from 2018...
Targeting BCL2 May Overcome Acquired Resistance in BRAF-Mutant Melanoma
Targeting BCL2 family proteins may counteract acquired resistance to BRAF and MEK inhibition in patients with BRAF-mutant metastatic melanoma, according to findings from a preclinical study published in Nature Communications. “Targeted therapy works by shutting down the main signal driving...
ASCO Remembers Karnofsky Award Recipient Maura L. Gillison, MD, PhD, Pioneer in HPV-Associated Cancers
Reprinted with permission from ASCO Connection, June 26, 2026. ASCO joins the oncology community in mourning the loss of Maura L. Gillison, MD, PhD. As a medical oncologist specializing in thoracic/head and neck cancers, and as a molecular epidemiologist, Dr. Gillison definitively characterized the ...
Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy
Tile-based radiation therapy (TBRT) implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy (SRT) in the phase III Radiation One and Done Study (ROADS), improving surgical bed control and overall survival while maintaining a comparable safety profile,...
I Miss My Life
Mr. A was a young professional who walked into my outpatient clinic one morning with his mother by his side. He wore a warm smile, yet there was a quiet heaviness beneath it. A few months earlier, he had been diagnosed with a malignant brain tumor and had undergone primary treatment. He was now...
Fertility Preservation Access Remains ‘Limited and Unequal’ for Many Girls and Young Women With Cancer
A new Columbia University School of Nursing systematic review published by Algave et al in the journal Cancer reveals access to fertility preservation care remains limited and unequal for girls and young women with cancer. Each year, more than 85,000 adolescents and young adults (AYAs)—individuals...
Next-Generation KRAS Inhibitors Show Promising Activity in Advanced Non–Small Cell Lung Cancer
Two investigational KRAS inhibitors showed activity in previously treated KRAS-mutant non–small cell lung cancer (NSCLC), according to findings presented during the Clinical Trials Plenary Session at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego. Elisrasib was ...
Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer
Existing agents such as statins and beta-blockers showed cardioprotective properties in select subgroups, but more treatments are needed to protect against heart failure in patients receiving treatment for cancer, according to findings from a systematic review and meta-analysis presented at the...
SENOMAC Trial: Omission of Completion Axillary Dissection Is Oncologically Safe in Expanded Breast Cancer Population
The international non-inferiority SENOMAC trial has confirmed that omitting completion axillary lymph node dissection (ALND) is oncologically safe (ie, a less intensive approach does not compromise outcomes) and substantially reduces patient-reported arm morbidity in patients with one or two...
TAPUR Marks a Decade of Innovation
In 2013, during the ASCO Annual Meeting, Richard L. Schilsky, MD, FACP, FSCT, FASCO, then ASCO’s Chief Medical Officer, presented a bold clinical trial concept during an educational session on the challenges of delivering precision medicine services in an oncology community care setting. The idea...
Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab
Patients with multiple myeloma who received a new immunotherapy combination had significantly longer progression-free survival and showed early signs of improved overall survival, according to findings from the phase III MonumenTAL-3 trial. Peter M. Voorhees, MD, Professor of Medicine at Wake...
Coming Out in the Exam Room
Preparing for a patient I was going to see in breast oncology clinic, I noticed she was single and that her partner was female. The information system at the hospital I was working in included a patient photograph along with the usual demographic and clinical information. The photograph had caught ...
‘The Science and Practice of Translation: Improving Cancer Outcomes Worldwide’
“Good morning, and welcome to the 62nd Annual Meeting of ASCO! ¡Buenos días, y bienvenidos a la sexagésima segunda reunión anual de ASCO! This is the world’s largest cancer research conference and the premier global platform for oncology innovation! But what brings us together today is not just...
Review of Breast Cancer News and Studies
Among the high-quality abstract presentations at ASCO and the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. The ASCO Post asked its Senior Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to offer his selection and thoughts on some...
Friends of Cancer Research Names Richard Pazdur, MD, to Board of Directors
Friends of Cancer Research announced the election of Richard Pazdur, MD, to its Board of Directors. Dr. Pazdur spent 26 years at the U.S. Food and Drug Administration, where he served as the founding director of the Oncology Center of Excellence and played a leading role in shaping the regulatory...
Combining Targeted Immunotherapies With Standard R-CHOP Delays Progression of Aggressive B-Cell Lymphomas
Results from the phase III frontMIND trial show that adding tafasitamab and lenalidomide to R-CHOP (rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) for first-line treatment can reduce tumor progression in patients with aggressive diffuse large B-cell lymphoma...
Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC
New findings from the phase III HARMONi-6 trial presented at the 2026 ASCO Annual Meeting showed that the investigational bispecific antibody ivonescimab combined with chemotherapy significantly improved overall survival compared with tislelizumab plus chemotherapy in patients with advanced...
Local Radiotherapy May Help Control Oligometastatic Breast Cancer
Local radiotherapy may help control disease spread in patients with oligometastatic breast cancer, according to findings from the OLIGOMA trial presented during the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026; Abstract 5611). “Currently, patients with oligometastatic ...
TAILORx and RxPONDER Trials Shift to a Discovery Platform
The ECOG-ACRIN Cancer Research Group, in collaboration with the SWOG Cancer Research Network, has launched a new initiative to analyze paired original and recurrent tumor specimens from two practice-changing breast cancer clinical trials. Through the translational study EA1241, researchers will...
Using Artificial Intelligence to Prescribe Cancer Drugs and Perform Other Tasks
In a recent article in The ASCO Post, we discussed increasing use of artificial intelligence (AI) in oncology and how physician-complementing AI can empower oncologists to be even better at what they do.1The reason AI is needed is that increasingly many variables need to be considered in cancer...
Facing a Year Ahead of Unprecedented Opportunities—and Challenges
This year has marked unprecedented progress against cancer—as well as challenges. According to findings in the American Cancer Society’s Cancer Statistics, 2026 report, the 5-year relative survival rate for all cancers combined has reached a milestone of 70% for individuals diagnosed between 2015...
Four Ways AI Is Transforming Patient Care—and What Lies Ahead
During her Presidential address at the 2025 ASCO Annual Meeting, Robin T. Zon, MD, FACP, FASCO, assessed how artificial intelligence (AI) is driving knowledge into action in the field of oncology, and acknowledged that “we are now at the crossroads of long-imagined possibilities and actionable...
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
Although treatment advances have increased the 5-year relative survival rates across all age groups, including a 15% increase for adolescents and young adults ages 15 to 39 years,1 it varies widely for some cancers among AYAs who are diagnosed with cancer. For example, AYAs have substantially worse ...
Losing Weight, Gaining Quality of Life in Early-Stage Breast Cancer
A telephone-based weight loss intervention improved physical function and other patient-reported outcomes among women with early-stage breast cancer and overweight or obesity, according to findings from the health outcomes (HO)-1 substudy of the phase III Breast Cancer WEight Loss (BWEL) trial...
New ASCO Guideline Fills Gap in Guidance on Rapidly Evolving Treatment Options in Thyroid Cancer
ASCO has issued a new clinical practice guideline on the use of systemic therapy for treatment of different types of thyroid cancer, a field that has changed substantially in recent years.1 “Despite a rather rapidly evolving field of targeted and nontargeted systemic agents in the management of...
Could AI Be Licensed to Practice Oncology?
Is artificial intelligence (AI) poised to practice medicine? It may be already. Earlier this year, the state of Utah allowed Doctronic, a health technology company using AI to make clinical decisions autonomously, to renew prescriptions for patients who request the service. Although Utah’s pilot...
Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib improved progression-free survival, produced a higher objective response rate, and showed a trend...
Acupuncture for Nocturia in Survivors of Prostate Cancer
Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality than the general population. The evidence supporting current treatment options for nocturia is weak. ...
AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS
Monitoring for relapse with an artificial intelligence (AI)-powered peripheral blood-based tool called AlloHeme demonstrated greater sensitivity in predicting relapse after hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) than ...
Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in BRCA/ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 and/or ATM alterations.1...
What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Debate
Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of trials are international studies investigating T-DXd as a potential treatment option for eligible...
Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity
Patients with advanced platinum-resistant ovarian cancer who had experienced disease progression on standard therapy exhibited clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results from a phase I clinical trial (ClinicalTrials.gov...
AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers
Researchers have developed an artificial intelligence (AI) tool that can identify small groups of cells most responsible for driving aggressive cancers. The tool, called SIDISH, offers scientists a clearer path to designing targeted therapies by showing which cells inside a tumor are most strongly...
Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma
A population of patients with highly refractory follicular lymphoma achieved long-standing responses with few significant adverse events from odronextamab monotherapy, according to findings of the ELM-2 study. The study outcomes were published by Tessoulin et al in Clinical Lymphoma, Myeloma &...
